Verapamil, propranolol, digitalis, and cardioversion have all been used to treat paroxysmal supraventricular tachycardia. Since 1955 adenosine triphosphate has also been used in some parts of Europe to treat acute episodes of paroxysmal supraventricular tachycardia, and the electrophysiological effects of this agent have been reviewed by Belhassen and Pelleg.' The effect of adenosine triphosphate on the sinus and atrioventricular nodes has been investigated in animals.2 3 The effects of adenosine triphosphate are largely mediated by its metabolite, adenosine. Adenosine, which is increased in the ischaemic myocardium, has been implicated in the causation of atrioventricular block.4 5 which lasted for seconds, and repeated administration produced neither tolerance nor cumulative effects. 3 The purpose of the present study was to determine the efficacy, rapidity of action, and side effects of adenosine triphosphate in the treatment of paroxysmal supraventricular tachycardia.
Patients and methods
We studied 11 episodes of tachycardia in 10 patients (6 men and 4 women, mean (SD) age 56 (15) years). The heart rate ranged from 146 to 200 beats per minute, and in each patient the rate was constant from minute to minute. The P wave was not seen in 8 (73%) episodes; it apparently occurred simultaneously with the QRS complex. The P wave was confined to the proximal portion of the ST segment in two patients so that the R-P' interval was shorter than the P'-R interval. One patient (case 3) had longer R-P' intervals than P'-R intervals, suggesting a fast-slow form of junctional re-entrant tachy- Undetectably IQw-0-2-5-0 13-30
Because diastolic blood pressure was undetectably low in four episodes, mean values of diastolic pressure were not calculated. Conversion: SI to traditional units-I kPa = 7-5 mm Hg.
cardia.'1 The QRS configuration was identical to that of sinus rhythm except in the patient with Wolff-Parkinson-White syndrome in whom the duration of the QRS complex was normal during tachycardia.
STUDY PROTOCOL
After we had measured blood pressure and had obtained a standard 12 lead electrocardiogram, we injected adenosine triphosphate intravenously as rapidly as possible (within 5 seconds). Eight attacks in eight patients were treated with 20 mg and three attacks in two patients were treated with 10 mg. Lead II or CM5 electrocardiograms were continuously recorded from just before the injection to one minute after the end of tachycardia or until two minutes after the end of adenosine triphosphate injection, and the electrocardiogram was then monitored for the next five minutes. We noted the interval between adenosine triphosphate injection and the end of tachycardia, the pause at termination, the pattern of interruption, side effects, and blood pressure three minutes after termination.
Results
Five episodes of tachycardia were treated with adenosine triphosphate within two hours and six episodes were treated between three and five hours after the beginning of the episode. Systolic blood pressure before treatment varied from 7.71 to 15-96 kPa (58 to 120 mm Hg). In three cases (four episodes) diastolic blood pressure was too low to measure with a sphygmomanometer.
The Figure shows a typical response on the electrocardiogram (lead CM5) to 20 mg of adenosine triphosphate (case 10). The heart rate during tachycardia was 160 beats/minute. The tachycardia ended 6-2 seconds after injection of the nucleotide, and this was followed by sinus rhythm with wide QRS complex and pronounced atrioventricular block. Regular sinus rhythm was restored seconds after the end of tachycardia, after an intervening period of atrioventricular dissociation. The patient complained of mild nausea which disappeared within 10 seconds.
All patients responded well to adenosine triphosphate. In the patient with sick sinus syndrome, however, a second episode of supraventricular tachycardia started five minutes after the end of the first episode. On two separate occasions a patient with Wolff-Parkinson-White syndrome was successfully treated with adenosine triphosphate. Table  2 summarises the effects of the nucleotide on the electrocardiograms obtained during the 11 episodes. Tachycardia ended within 15 seconds (mean 10-7 (3 4)) of the start of the injection of adenosine triphosphate. The first QRS complex appeared within four seconds of the end of tachycardia in 10 episodes; the remaining episode was followed by a pause lasting for approximately six seconds. The first QRS complex originated from the sinus node after six episodes, from the atrioventricular junction after four episodes, and from the ventricle after one episode. The longest R-R interval occurred between the first and the second heart beat or between the second and the third heart beat in six episodes, and after two episodes the longest R-R interval occurred immediately after the end of tachycardia. Sinus arrest or pronounced sinus bradycardia and atrioventricular block with junctional escape beats were common features at the end of tachycardia. Regular sinus rhythm was restored within 18 seconds of the end of tachycardia. No ventricular arrhythmias were precipitated. Blood pressure measured three minutes after the end of tachycardia was significantly higher than during tachycardia.
SIDE EFFECTS
Eight patients reported side effects, but these resolved within 20 choice. Verapamil is reported to be successful in most patients, 12 13 but it can cause hypotension or bradycardia and aggravate heart failure, especially in patients with myocardial disease14 or in those who have been treated with beta blockers. 15 The half life of intravenous verapamil has been estimnated to be 18-45 minutes in the initial rapid phase (a phase) and 3-6 hours in the later slow period (3phase), 16 17 and persist'enice of the active drug theplam comp'licate, the management of patients with side effects. A comparative study of adenosine and adenosine triphosphate in the dog showed that the nucleotide produced direct negative dromotropic and chronotropic effects on atrioventricular conduction and on atrioventricular junctional rhythm respectively.' DiMarco et al also reported a remarkable effect of adenosine for short term treatment of supraventricular tachycardia whenever re-entry through the atrioventricular node is involved. '18 These effects strongly suggest that adenosine triphosphate may be effective in terminating acute episodes of supraiventricular tachycardia that affect the atrioventricular node via the re-entry pathway. Previous reports had suggested that the actions of adenosine triphosphate on tachycardia are due to adenosine produced by hydrolysis of the nucleotide.36 Table 2 Timing of electrocardiogr-aphic events after injection of adenosine triphosphate 10 -70 mg of the nucleotide without harmful side effects. In the present study 10 mg of adenosine triphosphate successfully converted tachycardia to sinus rhythm in all three cases in which it was used. This result suggests that, in Japanese patients at least, doses of the nucleotide should start at 10 mg or less with a gradual increase in dose every two or three minutes until the tachycardia is terminated.
In conclusion, adenosine triphosphate has features that indicate that it may be one of the safest and the most effective methods of treating paroxysmal supraventricular tachycardia, but more extensive trials are needed to establish this. 
